share_log

和黃醫藥:和黃醫藥公佈2024年中期業績及最新業務進展

HUTCHMED: HUTCHMED Reports 2024 Interim Results and Provides Business Updates

HKEX ·  Jul 31 19:00

Summary by Futu AI

和黃醫藥(中國)有限公司公佈截至2024年6月30日止六個月的中期業績,總收入為3.057億美元,較去年同期下降43%。公司重申全年腫瘤/免疫業務綜合收入指引為3億至4億美元。FRUZAQLA®在美國市場表現強勁,上半年銷售額達1.305億美元。淨收益為2,580萬美元,現金及現金等價物和短期投資合計為8.025億美元。公司繼續推進關鍵臨床項目,並與國際合作夥伴進行戰略合作,加速新藥開發及商業化進程。
和黃醫藥(中國)有限公司公佈截至2024年6月30日止六個月的中期業績,總收入為3.057億美元,較去年同期下降43%。公司重申全年腫瘤/免疫業務綜合收入指引為3億至4億美元。FRUZAQLA®在美國市場表現強勁,上半年銷售額達1.305億美元。淨收益為2,580萬美元,現金及現金等價物和短期投資合計為8.025億美元。公司繼續推進關鍵臨床項目,並與國際合作夥伴進行戰略合作,加速新藥開發及商業化進程。
Hutchmed (China) Limited announced its interim results for the six months ended June 30, 2024, with total revenue of 0.3057 billion US dollars, a 43% decrease compared to the same period last year. The company reiterated its full-year guidance for combined revenue from its oncology/immunology business, which is expected to be between 0.3 billion and 0.4 billion US dollars. FRUZAQLA® performed strongly in the US market, with sales of 0.1305 billion US dollars in the first half of the year. Net profit was 25.8 million US dollars, and cash and cash equivalents together with short-term investments amounted to 0.8025 billion US dollars. The company continues to advance key clinical projects and collaborate with international partners to accelerate the development and commercialization of new drugs.
Hutchmed (China) Limited announced its interim results for the six months ended June 30, 2024, with total revenue of 0.3057 billion US dollars, a 43% decrease compared to the same period last year. The company reiterated its full-year guidance for combined revenue from its oncology/immunology business, which is expected to be between 0.3 billion and 0.4 billion US dollars. FRUZAQLA® performed strongly in the US market, with sales of 0.1305 billion US dollars in the first half of the year. Net profit was 25.8 million US dollars, and cash and cash equivalents together with short-term investments amounted to 0.8025 billion US dollars. The company continues to advance key clinical projects and collaborate with international partners to accelerate the development and commercialization of new drugs.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.